Cardiovascular diseases (CVD) are the number one cause of morbidity and death
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …

There are a number of methods that can be used for the preparation of enzyme-containing
lipid vesicles (liposomes) which are lipid dispersions that contain water-soluble enzymes in …

Nanoparticle immunogenicity and antigenicity have been under investigation for many
years. During the past decade, significant progress has been made in understanding what …

Intravascular administration of plasminogen activators is a clinically important thrombolytic
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …

A thrombus is a blood clot that forms in the lumen of an artery or vein, restricting blood flow
and causing clinical symptoms. Thrombosis is associated with many life‐threatening …

Nanotechnology is proven to provide certain benefits in drug delivery by improving solubility,
increasing uptake to target sites and changing pharmacokinetics profiles of traditional drugs …

Nanoparticle interactions with various components of the immune system are determined by
their physicochemical properties such as size, charge, hydrophobicity and shape …

Cardiovascular disorders are on the rise worldwide due to alcohol abuse, obesity,
hypertension, raised blood lipids, diabetes and age-related risks. The use of classical …

Enzymes today play a predominant role in the pharmaceutical industries due to their ability
to efficiently and selectively catalyze biochemical reactions in living systems. Since the …

Despite continued achievements in antithrombotic pharmacotherapy, difficulties remain in
managing patients at high risk for both thrombosis and hemorrhage. Utility of antithrombotic …